{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-311027","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2022-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.223712+00:00","generated_at":"2026-06-21T00:10:53.153181+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CEO RA Session II resigns; Chairman Sean Nolan appointed CEO; Sukumar Nagendran named President and Head of R&D","bullets":["RA Session II resigned as President and CEO effective Dec 16, 2022; remains on Board.","Sean Nolan (Chairman) appointed CEO immediately; compensation not yet finalized.","Sukumar Nagendran, M.D., appointed President and Head of R&D; Suyash Prasad becomes Chief Medical Officer.","Company will file separation terms later; compensation for Nolan and Nagendran to be amended.","Company to host investor call mid-January after FDA Type B meeting on GAN program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-311027","json":"https://secwatch.observer/filing/0001193125-22-311027.json","markdown":"https://secwatch.observer/filing/0001193125-22-311027.md","text":"https://secwatch.observer/filing/0001193125-22-311027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/0001193125-22-311027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/d398679d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T00:10:53.153181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09995af194","claim":"Suyash Prasad changed role as Chief Medical Officer at Taysha Gene Therapies, Inc..","evidence_excerpt":"Dr. Suyash Prasad’s title was changed from Chief Medical Officer and Head of Research and Development to Chief Medical Officer, effective as of Dr. Nagendran’s appointment.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/0001193125-22-311027-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"title changed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"80f5259998","claim":"Sean Nolan was appointed as Chief Executive Officer at Taysha Gene Therapies, Inc..","evidence_excerpt":"On December 16, 2022, the Board appointed Sean Nolan as the Company’s Chief Executive Officer, effective as of the effective time of Mr. Session’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/0001193125-22-311027-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"be5bf3dad6","claim":"Sukumar Nagendran was appointed as President and Head of Research and Development at Taysha Gene Therapies, Inc..","evidence_excerpt":"On December 16, 2022, the Board appointed Dr. Sukumar Nagendran as the Company’s President and Head of Research and Development, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/0001193125-22-311027-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Head of Research and Development"}],"fact_type":"executive_change"},{"claim_id":"d1d8a96d07","claim":"RA Session II resigned as President and Chief Executive Officer at Taysha Gene Therapies, Inc..","evidence_excerpt":"On December 16, 2022, RA Session II, the President and Chief Executive Officer of Taysha Gene Therapies, Inc. (the “ Company ”), resigned from his operating role, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522311027/0001193125-22-311027-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}